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Introduction
Retinal venous occlusive disease is the second most common retinal vascular disorder after diabetic retinopathy. Its prevalence has been shown to vary from 0.7 to 1.6% [1, 2] . Depending on the location of venous blockage, retinal vein occlusion (RVO) is classified as central RVO (CRVO), branch RVO (BRVO), or hemiretinal vein occlusion (HRVO).
Early recognition and treatment are important to avoid potentially significant visual morbidity. Occlusion or thrombosis of the retinal vein is associated with chronic glaucoma, atherosclerotic risk factors (age, diabetes, and hypertension), hyperviscosity, coagulopathy, smoking, and migraine [3] .
Many authors consider different pathogenetic mechanisms in most cases of CRVO and BRVO. CRVO can occur as a result of various pathologic insults, including compression of the vein (mechanical pressure due to arteriosclerotic changes in the central retinal artery and/or structural changes in the lamina cribrosa), hemodynamic disturbances (associated with hyperdynamic or sluggish circulation), vasculitis (e.g., sarcoidosis), and changes in the coagulating factors in the blood (e.g., deficiency of thrombolytic factors, increase in clotting factors). Hemicentral or hemispheric RVO, a variant of CRVO, is associated with congenital variation in central vein anatomy, and it may involve either the superior or the inferior half of the retina.
An idiopathic thrombus at an arteriovenous crossing site typifies the presentation of nearly all BRVOs. At arteriovenous crossing sites, the artery and the vein have a common adventitial sheath. Like systemic vascular disease, hypertrophy of the arterial wall media results in artery enlargement and rigidity. The venous lumen is thereby compressed and narrowed, causing endothelial cell damage and turbulent blood flow. Thrombus formation via platelet adherence and aggregation results in clinically evident BRVO [4] [5] [6] .
We present a case of recurrent nonischemic combined RVO (branch and hemicentral) in a patient with impaired fibrinolysis.
Case Report
A 61-year-old woman presented to our department with sudden vision loss in her right eye (RE). Visual acuity (VA) was 0.02 in her RE and 0.9 in her left eye. Intraocular pressure and the anterior ocular segment were normal in both eyes. Ophthalmoscopic examination of the left eye was normal, but the RE revealed retinal flame-shaped hemorrhage and cotton wool spots (Fig. 1a ). The early phase of fluorescein angiography showed multiple areas of hypofluorescence due to intraretinal hemorrhages and leakage of dye involving the fovea in the late phase ( Fig. 1b, c ). Optical coherence tomography (OCT) showed an accumulation of intraretinal fluid (Fig. 2a ). The patient was otherwise healthy and had no other ocular or systemic diseases. The results of electrocardiography and laboratory tests (full blood count and erythrocyte sedimentation rate or plasma viscosity, urea, electrolytes, creatinine, random blood glucose, random cholesterol and HDL cholesterol, plasma protein electrophoresis, and thyroid function), including blood coagulation and the immune system, were normal. She was treated with 3 consecutive intravitreal applications of anti-vascular endothelial growth factor (anti-VEGF; bevacizumab) due to cystoid macular edema, with improvement of the best corrected VA (BCVA) to 0.9 and full resolution of the intraretinal fluid on OCT (Fig. 2b) .
After 8 months, she presented again to our department with acute blurring of vision in the same (right) eye with a BCVA of 0.5. An ophthalmoscopic examination of the RE revealed retinal flame-shaped hemorrhages and cotton wool spots, but this time in a completely inferior part of the retina. Fluorescein angiography of the RE showed signs of nonischemic HRVO (Fig. 3a, b ). She was treated with a single intravitreal application of anti-VEGF (ranibizumab) due to perifoveal edema as seen on OCT, with resolution of the intraretinal fluid and improvement of the BCVA to 0.9 (Fig. 3c, d) .
Further laboratory tests including prothrombin time, activated partial thromboplastin time, protein C, protein S, factor V Leiden, antithrombin III, homocysteine, antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody were performed and showed negative results.
A molecular analysis was also performed. The patient was tested for five gene variants: factor V Leiden (FVQ506), factor II (G20210A), 5,10-methylenetetrahydrofolate reductase (MTHFR) (C677T), plasminogen activator inhibitor-1 (PAI-1) (4G/4G, 5G/5G, and 4G/5G), and angiotensin-converting enzyme (del/ins). By amplifying the promoter region of the gene for PAI-1, the insertion-deletion genotype (4G/5G) was determined in the patient. Other tests showed a normal type of the tested genes.
Discussion
RVO is a disease of the older population (aged >65 years). The major risk factors are hypertension, diabetes, and atherosclerosis. Other risk factors are glaucoma, syphilis, sarcoidosis, vasculitis, anemia, increased orbital or intraocular pressure, hyperviscosity syndromes (multiple myeloma, Waldenström macroglobulinemia, and leukemia), high homocysteine levels, sickle cells, and HIV [7] . In addition to ruling out known causes of vasculitis, such as Behçet disease, sarcoidosis, syphilis, and Lyme disease, tests to consider include levels of serum homocysteine, antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody. In our case, no abnormality was observed.
PAI-1 is a fast-acting inhibitor of tissue-type plasminogen activator. Marcucci et al. [8] found elevated levels of PAI-1 in patients with CRVO compared with those in control subjects. PAI-1, also known as endothelial plasminogen activator inhibitor or serpin E1, is a protein encoded by the serpine 1 gene in humans. The main function of PAI-1 entails the inhibition of urokinase plasminogen activator, an enzyme responsible for the cleavage of plasminogen to form plasmin. Elevated PAI is a risk factor for thrombosis and atherosclerosis [9] . Presently, routine testing of patients for PAI-1 is not recommended. Laboratory evaluations are not recommended in typical BRVO, while atypical cases such as BRVO occurring in young patients, bilateral BRVO, or BRVO occurring at a site not associated with an arteriovenous crossing warrant a laboratory workup.
The PAI-1 gene is serpine 1, located on chromosome 7 (7q21.3-q22). There is a common polymorphism, known as 4G/5G, in the promoter region. The 4G allele frequency of the PAI-1 gene, associated with hypofibrinolysis, was found to be 64% in cases of thrombophilia in the study by Glueck et al. [10] , and much less in control cases. The PAI-1 gene 4G allele was associated with RVO with an odds ratio of 1.94. Increased PAI-1 activity in patients with RVO was determined also by PAI-1 4G/5G polymorphisms by Gori et al. [11] . PAI-1 activity was determined by the PAI-1 4G/5G polymorphism by polymerase chain reaction and restriction length fragment polymorphism. In another study, Mattes et al. [12] found that among all patients with RVO, 54.5% had the PAI-1 4G/5G gene polymorphism. Conversely, for the angiotensin-converting enzyme (ins/del) and PAI-1 (4G/5G) mutations, no difference was observed between the genotypes of patients with RVO and those of control participants in the study by Russo et al. [13] and Kuhli-Hattenbach et al. [14] . Homozygosity for the PAI-1 4G/5G gene polymorphism itself was not associated with an increased risk for RVO, with no significant difference in PAI-1 4G/5G genotype distribution with either retinal artery or vein occlusion. However, previous studies have shown no clinical appearance of unilateral recurrent nonischemic BRVO and HRVO in a patient with no systemic associations and a normal laboratory workup for thrombophilia [15] .
Conclusion
Our case illustrates a unique presentation of unilateral recurrent nonischemic BRVO and HRVO in the same eye in a patient with no systemic associations and a normal laboratory workup for thrombophilia. A molecular analysis of the genes associated with thrombophilia showed that the PAI-1 4G/5G polymorphism genotype could be responsible for the retinal venous occlusive disease in our patient. Few and conflicting data are available for this genotype of thrombophilia associated with RVO. Our case demonstrated genetically impaired fibrinolysis as the only risk factor for this condition. 
